Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Major Wholesalers' 1st-half Sales Unexpectedly Good
November 11, 2002
- Meiji Seika, Bayer to Comarket Bayclear Plus
November 11, 2002
- Kuraya Sanseido to Achieve 2% Operating Profit Rate by Further Cutting Costs
November 4, 2002
- Takeda Develops Simulation Software to Predict Prognosis of Diabetic Complications
November 4, 2002
- Yoshitomi to Further Specialize in Psychiatric Field
November 4, 2002
- Nihon Schering Introduces HTRF Technology for HTS
November 4, 2002
- IMS Japan to Communicate Closely with Wholesalers to Dispel Misunderstanding
November 4, 2002
- JCQHC to Start Publishing Therapeutic GLs from Next Year
November 4, 2002
- Drug Market to Expand to \5,965 Bil. in FY2002: Analyst
November 4, 2002
- PRESS SEMINAR
November 4, 2002
- BUSINESS NEWS IN BRIEF
November 4, 2002
- BUSINESS BULLETIN
November 4, 2002
- Sysmex: FY2002 Half-year Profit Forecasts Revised Upward
November 4, 2002
- RESEARCH & DEVELOPMENT BULLETIN
November 4, 2002
- Eiken: FY2002 Profit Forecasts Revised Downward
November 4, 2002
- Shionogi Licenses Patents on BNP to Kyowa Medex
November 4, 2002
- MEET THE LEADERS (9)
November 4, 2002
- Roche to Launch Fully Automated Gene Detection Module in 2004
November 4, 2002
- REGULATORY BULLETIN
November 4, 2002
- DIAGNOSTIC NEWS IN BRIEF
November 4, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…